🇺🇸 FDA
Pipeline program

STN1010904, Placebo (vehicle), STN1010904

101090401IN

Phase 2 small_molecule active

Quick answer

STN1010904, Placebo (vehicle), STN1010904 for Fuchs Endothelial Corneal Dystrophy (FECD) is a Phase 2 program (small_molecule) at Santen Oy with 1 ClinicalTrials.gov record(s).

Program details

Company
Santen Oy
Indication
Fuchs Endothelial Corneal Dystrophy (FECD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials